
The purpose of this study was to investigate severe adverse events zzso after therapeutic zzso vaccination for advanced cancer zzso We investigated zzso following personalized zzso zzso in 500 advanced cancer patients, including 174 zzso 74 zzso 51 pancreatic and 43 gastric cancer zzso The number of vaccination cycles varied widely, from 3 to zzso The severity of adverse events was scored according to the National Cancer Institute Common zzso zzso for zzso Events version 3, and events with a grade of zzso were defined as zzso and were evaluated by the Institutional Safety zzso zzso A total of 215 zzso in 102 patients were recorded during the vaccine zzso The main causes for these events were cancer progression zzso zzso in 78 zzso combined cancer treatments other than vaccination (35 in 21 zzso diseases other than cancer (20 in 19 zzso zzso vaccines (6 in 6 zzso and suicide (1 in 1 zzso The 6 zzso zzso all grade 3, consisted of skin reactions at each injection site, zzso around the injection site, zzso of the head and neck regions, zzso zzso bleeding and zzso zzso Both cellular and zzso responses to the vaccinated peptides were highly zzso in all 6 of these patients, indicating the involvement of zzso immune responses in these zzso The clinical responses in these 6 patients consisted of 2 partial responses and 4 stable zzso The majority of zzso after zzso vaccination for advanced cancer patients were caused by cancer zzso The appearance of zzso zzso except inflammatory injection site zzso was unexpected, and zzso the zzso was very zzso Our results suggest that physicians should be on guard for these rare zzso associated with zzso immune zzso 

